White Paper Says U.S. Most-Favored-Nation Pricing Is Reshaping Biopharma Launch Plans
A survey of 16 manufacturers points to changes in launch sequencing and pricing governance.
Related stories
A. O. Smith Reports Q3 Adjusted Earnings, Revises 2026 EPS Guidance
A. O. Smith reported Q3 adjusted earnings and revised full-year 2026 adjusted EPS guidance to exclude its China business. The headline also reports a drop in net sales but gives no
M impact | EQUITY | Oct 29, 2026, 01:28 PM UTC
IndiGo Reports Rs 1,879 Crore Q2 Loss as Fuel Costs, Rupee Weigh
InterGlobe Aviation reported a consolidated net loss of Rs 1,879.1 crore for the July-September quarter of FY27, despite strong revenue growth.
M impact | EQUITY | Oct 29, 2026, 01:27 PM UTC
Kunlun Tech Reports Q3 Net Loss of 1.1 Billion Yuan
M impact | EQUITY | Oct 29, 2026, 01:27 PM UTC
Gulf Bourses Retreat as Bank Stocks Ease on War Worries
Gulf bourses retreated as bank stocks eased amid worries over the wars in Yemen and Iran.
M impact | EQUITY | Oct 29, 2026, 01:27 PM UTC
Cosmos Health Reports 12,050 U.S. Subscriptions, Monthly Value of $1.79M
Cosmos Health said it had 12,050 active U.S. subscriptions as of Oct. 28, up 92% in two weeks. Preliminary, unaudited monthly subscription value rose 94% to $1.79 million at standa
M impact | EQUITY | Oct 29, 2026, 01:27 PM UTC
Klabin Publishes Q3 2026 Results Presentation
Klabin published its third-quarter 2026 results presentation. The available text says net revenue rose 3%.
M impact | EQUITY | Oct 29, 2026, 01:26 PM UTC